Raymond James raised the firm’s price target on Johnson & Johnson to $164 from $162 and keeps an Outperform rating on the shares. The firm ...

Morgan Stanley raised the firm’s price target on Johnson & Johnson to $169 from $164 and keeps an Equal Weight rating on the shares after ...

J&J’s comments and guidance update come as the company kicks off 2025’s first-quarter earnings round for large drugmakers.

Health care giant Johnson & Johnson expects about $400 million in tariff-related costs this year. The costs will be felt ...